{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:31:52Z","timestamp":1773779512963,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["RV-MM-PI-0745"],"award-info":[{"award-number":["RV-MM-PI-0745"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00432-019-03101-z","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T16:23:51Z","timestamp":1575303831000},"page":"749-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)"],"prefix":"10.1007","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-7592","authenticated-orcid":false,"given":"Annamaria","family":"Brioli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Manz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas Christoph","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Prange-Krex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Fabisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Illmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Krammer-Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars-Olof","family":"M\u00fcgge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"3101_CR1","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1114138","journal-title":"N Engl J Med"},{"key":"3101_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473. https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"3101_CR3","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1182\/blood.V126.23.4239.4239","volume":"126","author":"T Facon","year":"2015","unstructured":"Facon T, Hulin C, Dimopoulos MA et al (2015) A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low-dose dexamethasone on the first trial. Blood 126:4239","journal-title":"Blood"},{"key":"3101_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0359-7","author":"SA Holstein","year":"2019","unstructured":"Holstein SA, Suman VJ, McCarthy PL (2019) Commentary on \u201cIs posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma\u201d by Giovanni Barosi and Robert Peter Gale. Leukemia. https:\/\/doi.org\/10.1038\/s41375-018-0359-7","journal-title":"Leukemia"},{"key":"3101_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749\u2013757","journal-title":"Br J Haematol"},{"key":"3101_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C et al (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20:57\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30687-9","journal-title":"Lancet Oncol"},{"key":"3101_CR7","first-page":"396","volume":"130","author":"JR Jones","year":"2017","unstructured":"Jones JR, Weinhold N, Ashby CC et al (2017) The mutational landscape of relapse in high risk myeloma is significantly impacted by the depth of response but not maintenance lenalidomide. Blood 130:396","journal-title":"Blood"},{"key":"3101_CR8","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520. https:\/\/doi.org\/10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"key":"3101_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ et al (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122\u20131128. https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"3101_CR10","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","volume":"32","author":"A Larocca","year":"2018","unstructured":"Larocca A, Dold SM, Zweegman S et al (2018) Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia 32:1697\u20131712. https:\/\/doi.org\/10.1038\/s41375-018-0142-9","journal-title":"Leukemia"},{"key":"3101_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"M-V Mateos","year":"2010","unstructured":"Mateos M-V, Oriol A, Mart\u00ednez-L\u00f3pez J et al (2010a) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11:934\u2013941. https:\/\/doi.org\/10.1016\/S1470-2045(10)70187-X","journal-title":"Lancet Oncol"},{"key":"3101_CR12","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"M-V Mateos","year":"2010","unstructured":"Mateos M-V, Richardson PG, Schlag R et al (2010b) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol Off J Am Soc Clin Oncol 28:2259\u20132266. https:\/\/doi.org\/10.1200\/JCO.2009.26.0638","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3101_CR13","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","volume":"120","author":"M-V Mateos","year":"2012","unstructured":"Mateos M-V, Oriol A, Mart\u00ednez-L\u00f3pez J et al (2012) Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120:2581\u20132588. https:\/\/doi.org\/10.1182\/blood-2012-05-427815","journal-title":"Blood"},{"key":"3101_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"M-V Mateos","year":"2018","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M et al (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378:518\u2013528. https:\/\/doi.org\/10.1056\/NEJMoa1714678","journal-title":"N Engl J Med"},{"key":"3101_CR15","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC et al (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1770\u20131781. https:\/\/doi.org\/10.1056\/NEJMoa1114083","journal-title":"N Engl J Med"},{"key":"3101_CR16","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT et al (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35:3279\u20133289. https:\/\/doi.org\/10.1200\/JCO.2017.72.6679","journal-title":"J Clin Oncol"},{"key":"3101_CR17","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P. Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P et al (2017) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 28:52\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdx096","journal-title":"Annals of Oncology"},{"key":"3101_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/0021-9681(85)90123-7","volume":"38","author":"M Palta","year":"1985","unstructured":"Palta M, Amini SB (1985) Consideration of covariates and stratification in sample size determination for survival time studies. J Chronic Dis 38:801\u2013809","journal-title":"J Chronic Dis"},{"key":"3101_CR19","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M et al (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759\u20131769. https:\/\/doi.org\/10.1056\/NEJMoa1112704","journal-title":"N Engl J Med"},{"key":"3101_CR20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F et al (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371:895\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1402888","journal-title":"N Engl J Med"},{"key":"3101_CR21","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos M-V et al (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125:2068\u20132074. https:\/\/doi.org\/10.1182\/blood-2014-12-615187","journal-title":"Blood"},{"key":"3101_CR22","first-page":"1854","volume":"130","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn C, Davies FE, Cairns D et al (2017) Continuous treatment with lenalidomide improves outcomes in newly diagnosed myeloma patients not eligible for autologous stem cell transplant: results of the myeloma XI trial. Blood 130:1854","journal-title":"Blood"},{"key":"3101_CR23","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389\u20132430. https:\/\/doi.org\/10.1002\/sim.2712","journal-title":"Stat Med"},{"key":"3101_CR24","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"3101_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906\u2013917. https:\/\/doi.org\/10.1056\/NEJMoa0801479","journal-title":"N Engl J Med"},{"key":"3101_CR26","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","volume":"297","author":"HGC Van Spall","year":"2007","unstructured":"Van Spall HGC, Toren A, Kiss A, Fowler RA (2007) Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297:1233\u20131240. https:\/\/doi.org\/10.1001\/jama.297.11.1233","journal-title":"JAMA"},{"key":"3101_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman S, Engelhardt M, Larocca A, EHA SWG on \u2018Aging and Hematology\u2019 (2017a) Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol 29:315\u2013321. https:\/\/doi.org\/10.1097\/CCO.0000000000000395","journal-title":"Curr Opin Oncol"},{"key":"3101_CR28","doi-asserted-by":"crossref","unstructured":"Zweegman S, Levin M-D, Klein SK et al (2017) Feasibility and efficacy of dose adjusted melphalan\u2014prednisone\u2014bortezomib in patients\u2009\u2265\u200975\u00a0years with newly diagnosed multiple myeloma; preliminary results of the phase II HOVON 123 study. Haematol 22nd Congrress Eur Haematol Assoc 102:112 (P340)","DOI":"10.1182\/blood.V128.22.3305.3305"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-03101-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T11:08:09Z","timestamp":1665140889000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-03101-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["3101"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-03101-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AB received honoraria and travel support from Celgene, Takeda, Gilead and Janssen, honoraria from Sanofi and research support from Celgene; KM has no conflicts of interests to report; MP has no conflicts of interests to report; LOM received honoraria and travel support from Bristol-Myers Squibb, Celgene, Janssen, Novartis, Takeda and research support from Celgene; the other authors have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}